Advances in the molecular genetics of acute leukemia
- 27 Downloads
Acute leukemias are characterized by the unrestrained clonal proliferation of hematopoietic precursor cells coupled with aberrant or arrested differentiation. The molecular basis of hematopoiesis and leukemogenesis is still being defined, yet it is increasingly evident that acute leukemias have recurrent molecular features that can be exploited for diagnostic, prognostic, and therapeutic purposes. Modern molecular technologies already influence treatment strategies for these diseases, and it is likely that as such technology matures it will have an increasing impact on all aspects of acute leukemia management. This article reviews recent developments in the molecular classification, prognostication, and treatment of the acute leukemias.
Unable to display preview. Download preview PDF.
- 4.Golub TR, Slonim DK, Tamayo P, et al.: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531–537. This article is proof of principle that gene expression patterns can be used to classify human disease.PubMedCrossRefGoogle Scholar
- 8.Yeoh EJ, Ross ME, Shurtleff SA, et al.: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133–143. Demonstrates that the gene expression patterns of diagnostic ALL samples cluster with known clinical and cytogenetic features of the disease.PubMedCrossRefGoogle Scholar
- 9.Valk PJ, Verhaak RG, Beijen MA, et al.: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617–1628. Demonstrates that the gene expression patterns of diagnostic AML samples cluster with known clinical and cytogenetic features of the disease.PubMedCrossRefGoogle Scholar
- 21.Bullinger L, Dohner K, Bair E, et al.: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004, 350:1605–1616. Demonstrates that the gene expression patterns of diagnostic AML samples cluster with known clinical and cytogenetic features of the disease.PubMedCrossRefGoogle Scholar
- 29.Mulford DA, Maslak PG, Weiss MA, et al.: Reducing standard postremission chemotherapy in acute promyelocytic leukemia (APL) with risk-adapted therapy. Blood 2003, 102:619a-620a.Google Scholar
- 35.Lodie TA, Radomska HS, Donato JD, et al.: PML-RARalpha induces ATRA-sensitive delocalization of the critical granulocytic differentiation factor C/EBPalpha to a microspecked nuclear pattern in t(15;17) APL. Blood 1999, 94:692a.Google Scholar
- 36.WengAP, Ferrando AA, Lee W, et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269–271. This article reports common activating mutations in NOTCH1 and presents a rationale for a new clinical strategy for the treatment of T-cell ALL.PubMedCrossRefGoogle Scholar
- 37.Den Boer ML, Harms DO, Pieters R, et al.: Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003, 21:3262–3268. The authors identify gene signatures in diagnostic bone marrow cells that are associated with resistance to specific chemotherapy drugs.CrossRefGoogle Scholar
- 39.Leith CP, Kopecky KJ, Godwin J, et al.: Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997, 89:3323–3329.PubMedGoogle Scholar
- 45.Urano W, Taniguchi A, Yamanaka H, et al.: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002, 12:183–190.PubMedCrossRefGoogle Scholar
- 46.Byrd JC, Mrozek K, Dodge RK, et al.: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325–4336.PubMedCrossRefGoogle Scholar